Related Experiment Video

Updated: May 23, 2026

Assessment of Vascular Function in Patients With Chronic Kidney Disease
08:50

Assessment of Vascular Function in Patients With Chronic Kidney Disease

Published on: June 16, 2014

Elevated serum adipocyte fatty acid-binding protein concentrations are independently associated with renal

Mutsumi Iwamoto1, Toru Miyoshi, Masayuki Doi

  • 1Department of Cardiology, Kagawa Prefectural Central Hospital, Kagawa, Japan.

Cardiovascular Diabetology
|March 22, 2012
PubMed

Insights

Adipocyte fatty acid-binding protein (A-FABP) levels correlate with reduced kidney function and more severe coronary artery disease. Higher A-FABP indicates a greater risk of chronic kidney disease and multi-vessel disease in patients with stable angina.

Area of Science:

  • Cardiovascular Research
  • Nephrology
  • Biomarker Discovery

Background:

  • Chronic kidney disease (CKD) is a known risk factor for cardiovascular events.
  • Adipocyte fatty acid-binding protein (A-FABP) is implicated in the development of atherosclerosis.

Purpose of the Study:

  • To investigate the association between plasma A-FABP levels and renal function in patients with stable angina pectoris.
  • To explore the role of A-FABP in the interplay between kidney dysfunction and coronary artery disease severity.

Main Methods:

  • 221 patients with coronary artery stenosis underwent assessment.
  • Chronic kidney disease (CKD) was defined by estimated glomerular filtration rate (eGFR) < 60 ml/min/1.73 m2.
  • Serum A-FABP levels were measured using enzyme-linked immunosorbent assay; coronary stenosis severity was assessed via modified Gensini score.

Main Results:

  • Serum A-FABP levels showed a significant inverse correlation with eGFR (r = -0.41, p < 0.01) and a positive correlation with coronary artery stenosis severity (r = 0.16, p = 0.02).
  • Patients with A-FABP levels above the median (20.3 ng/ml) had a higher prevalence of CKD (57% vs. 27%) and multi-vessel disease (64% vs. 48%).
  • Higher A-FABP levels were independently associated with three-vessel disease (OR, 2.26; 95% CI, 1.28-3.98; p < 0.01).

Conclusions:

  • Serum A-FABP may play a significant role in the complex relationship between renal dysfunction and coronary atherosclerosis.
  • A-FABP could serve as a potential biomarker linking kidney health and cardiovascular disease progression.
Abstract

Related Concept Videos

Factors Affecting Protein-Drug Binding: Patient-Related Factors01:29

Factors Affecting Protein-Drug Binding: Patient-Related Factors

Protein-drug binding, a pivotal aspect of pharmacokinetics, is subject to considerable variability influenced by an array of patient-related factors. The intricate interplay of age, individual differences, and pathological conditions significantly impact the binding dynamics and subsequent pharmacological effects.
Age stands as a key determinant in protein-drug binding. Neonates, characterized by low albumin content, experience heightened concentrations of unbound drugs such as phenytoin and...
Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers01:19

Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers

Cardiac biomarkers are critical in diagnosing, prognosing, and managing cardiovascular diseases. Routine measurement of specific biomarkers such as B-type natriuretic peptide (BNP), C-reactive protein (CRP), and homocysteine (Hcy) is common practice in clinical settings to evaluate heart function and predict cardiovascular events.
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors01:30

Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors

Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...
External Anatomy of the Kidney01:21

External Anatomy of the Kidney

The kidneys are a pair of bean-shaped organs in the human body that play a critical role in maintaining overall health. They filter out waste products from the blood, regulate blood pressure, maintain electrolyte balance, and stimulate the production of red blood cells.
The kidneys are located in the retroperitoneal space on either side of the vertebral column, protected posteriorly by the 11th and 12th ribs. The right kidney sits slightly lower than the left owing to the presence of the liver...
Serum Studies: Renal Function Tests01:24

Serum Studies: Renal Function Tests

Renal function tests are crucial for assessing kidney health, monitoring disease progression, and evaluating the kidneys' efficiency in waste elimination, fluid balance, and electrolyte regulation. These tests offer critical insights into kidney function, even though routine measurements may appear normal until there is a significant decline in the glomerular filtration rate or GFR. Typically, signs of kidney impairment only become evident when the GFR falls to about 50% of its normal level.
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...